1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.

Nine Drugs Added to FDA Watch List including new oxycontin tablets and Embeda

By davestate, Apr 26, 2011 | | |
  1. davestate
    April 22, 2011 — The US Food and Drug Administration (FDA) has issued its latest list of drugs to monitor after having identified potential signs of serious risks or new safety information in the agency's Adverse Event Reporting System (AERS).

    The quarterly watch list consists of 9 medications that treat conditions ranging from arthritis to schizophrenia. The agency is studying them to determine whether they are causally linked to the possible risks reported through AERS from October 1, 2010, through December 31, 2010. If a link is established, the FDA then would consider some form of regulatory action, such as revising the drug's label information, requiring a Risk Evaluation and Mitigation Strategy (REMS), or gathering more data to better characterize the risk.
    The FDA cautions that a drug's appearance on the watch list does not mean the agency has determined that the drug actually poses the health risk in question. Accordingly, physicians should not stop prescribing these drugs, nor should patients stop taking them.
    Since the last quarter of 2010, 1 drug on the current list — an antiarrhythmic agent called dronedarone (Multaq, Sanofi-Aventis) — has prompted increased FDA vigilance. In February, the agency alerted clinicians to cases of rare but severe liver injury, including 2 cases of acute liver failure, in patients treated with dronedarone. The agency also added information about the potential risk of liver injury to the drug's label.
    Potential Signals of Serious Risks/New Safety Information Identified by AERS, October to December 2010



  1. Balzafire
    Very interesting that the new oxycontin OP is listed on that chart as a choking and gastrointestinal obstruction hazard.
  2. davestate
    It's says on the patient info leaflet and has been reported by users that passing of "ghost tablets" has been observed. With the slowing of peristalsis caused by the opiate on the gastrointestinal tract, perhaps there is a risk of obstruction by formation of a bezoar by an accumulation of these "ghost tablets", that is the tablet has released all it's medication, but the binders and inactive do not get broken down and stay in the shape of the pill. They seem like they could be a risk for blocking narrow parts of the digestive system, especially the appendix, or if a person had surgery involving the intestines or stomach and were at risk for adhesions, stenosis or obstruction. I wouldn't want to be taking them, that's for sure

    It would be good if there were any case reports detailing these problems, there must be something out there if the FDA has reason for concern. If anyone finds anything, be sure to update this thread
To make a comment simply sign up and become a member!